Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx

Tumor heterogeneity may impact immunohistochemical (IHC) interpretation, thus potentially affecting decision making by treating oncologists for cancer patient management. Programmed cell death ligand-1 (PD-L1) IHC 22C3 pharmDx is a companion diagnostic used as an aid in identifying patient eligibili...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalpakoff, Megan, Hund, Stephanie, Musser, Jeanette, Roach, Charlotte, Apostolaki, Angeliki, Vilardo, Monika, Peltz, Lindsay, Watts, Brittany, LaPlaca, Chris, Tabuena-Frolli, Siena, DiMaio, Michael A., Welcher, Rosanne, Kulangara, Karina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505133/
https://www.ncbi.nlm.nih.gov/pubmed/33973887
http://dx.doi.org/10.1097/PAI.0000000000000941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505133/
https://www.ncbi.nlm.nih.gov/pubmed/33973887
http://dx.doi.org/10.1097/PAI.0000000000000941

Ejemplares similares